Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization

Launched by SEUNG-JUNG PARK · Dec 25, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called Hybrid Coronary Revascularization, which combines two methods to improve blood flow in the heart for people with multiple blocked arteries. The main goal is to see how effective and safe this approach is when used in everyday medical practice. If you are 20 years or older and have coronary artery disease that affects multiple blood vessels, including a specific artery called the left anterior descending artery, you might be eligible to participate. However, those who have had a previous heart surgery called coronary artery bypass grafting (CABG) or have a life expectancy of less than one year cannot join.

If you decide to participate in this trial, you will be asked to give your written consent and will receive care related to the Hybrid Coronary Revascularization procedure. The study is currently recruiting participants, and it's open to people of all genders. This trial aims to gather important information that could help improve treatment options for individuals with heart disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 20 and more
• • Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
• • Written consent
• Exclusion Criteria:
• • Previous CABG(coronary artery bypass graft)
• • Life expectancy ≤1 year